Hannah M. Seagle
@hannah-m-seagle.bsky.social
PhD Candidate, Human Genetics, Vanderbilt University
I am excited to share that our paper has been officially published at AJHG!
www.cell.com/ajhg/fulltex...
www.cell.com/ajhg/fulltex...
Genomics-informed drug-repurposing strategy identifies two therapeutic targets for preventing liver disease associated with metabolic dysfunction
We prioritized 57 druggable targets from 212 putative causal genes of metabolic-dysfunction-associated
steatotic liver disease (MASLD). Using a drug-repurposing analysis that integrated
protein struct...
www.cell.com
August 7, 2025 at 3:44 PM
I am excited to share that our paper has been officially published at AJHG!
www.cell.com/ajhg/fulltex...
www.cell.com/ajhg/fulltex...
I am excited to share our new preprint “Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.” www.medrxiv.org/content/10.1.... 1/n
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease
Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinar...
www.medrxiv.org
March 19, 2025 at 6:27 PM
I am excited to share our new preprint “Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.” www.medrxiv.org/content/10.1.... 1/n
Excited to share our work on drug repurposing for metabolic dysfunction-associated steatotic liver disease this week at the Keystone Symposia meeting. I am also so honored and grateful to receive a scholarship award!
February 24, 2025 at 3:28 PM
Excited to share our work on drug repurposing for metabolic dysfunction-associated steatotic liver disease this week at the Keystone Symposia meeting. I am also so honored and grateful to receive a scholarship award!